BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 38404585)

  • 21. Transarterial Chemoembolization Combined With Apatinib Plus PD-1 Inhibitors for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Multicenter Retrospective Study.
    Xia WL; Zhao XH; Guo Y; Hu HT; Cao GS; Li Z; Fan WJ; Xu SJ; Li HL
    Clin Transl Gastroenterol; 2023 May; 14(5):e00581. PubMed ID: 36920551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of Peripheral Blood Biomarkers With Response to Anti-PD-1 Immunotherapy for Patients With Deficient Mismatch Repair Metastatic Colorectal Cancer: A Multicenter Cohort Study.
    Cheng YK; Chen DW; Chen P; He X; Li PS; Lin ZS; Chen SX; Ye SB; Lan P
    Front Immunol; 2022; 13():809971. PubMed ID: 35185898
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neutrophil-to-Lymphocyte Ratio and Early Tumor Shrinkage as Predictive Biomarkers in Unresectable Hepatocellular Carcinoma Patients Treated With Lenvatinib, PD-1 Inhibitors, in Combination With TACE.
    Qu S; Wu D; Hu Z
    Technol Cancer Res Treat; 2023; 22():15330338231206704. PubMed ID: 37849287
    [No Abstract]   [Full Text] [Related]  

  • 24. Interim efficacy and safety of PD-1 inhibitors in preventing recurrence of hepatocellular carcinoma after interventional therapy.
    Qiao W; Wang Q; Hu C; Zhang Y; Li J; Sun Y; Yuan C; Wang W; Liu B; Zhang Y
    Front Immunol; 2022; 13():1019772. PubMed ID: 36389724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. C-Reactive Protein Levels Predict Responses to PD-1 Inhibitors in Hepatocellular Carcinoma Patients.
    Zhang Y; Lu L; He Z; Xu Z; Xiang Z; Nie RC; Lin W; Chen W; Zhou J; Yin Y; Xie J; Zhang Y; Zheng X; Zhu T; Cai X; Li P; Chao X; Cai MY
    Front Immunol; 2022; 13():808101. PubMed ID: 35185894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients.
    Mazzaschi G; Minari R; Zecca A; Cavazzoni A; Ferri V; Mori C; Squadrilli A; Bordi P; Buti S; Bersanelli M; Leonetti A; Cosenza A; Ferri L; Rapacchi E; Missale G; Petronini PG; Quaini F; Tiseo M
    Lung Cancer; 2020 Oct; 148():1-11. PubMed ID: 32768804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoadjuvant transarterial chemoembolization (TACE) plus PD-1 inhibitor bridging to tumor resection in intermediate-stage hepatocellular carcinoma patients.
    Zhu C; Dai B; Zhan H; Deng R
    Ir J Med Sci; 2023 Jun; 192(3):1065-1071. PubMed ID: 35996068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-world treatment patterns and outcomes for patients with advanced hepatocellular carcinoma initially treated with PD-1 inhibitors.
    Zou H; Ge Y; Chen W; Yao D; Oi Lam Ung C; Lai Y; Hu H
    Int Immunopharmacol; 2024 May; 132():111947. PubMed ID: 38552296
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD8
    Duchemann B; Naigeon M; Auclin E; Ferrara R; Cassard L; Jouniaux JM; Boselli L; Grivel J; Desnoyer A; Danlos FX; Mezquita L; Caramella C; Marabelle A; Besse B; Chaput N
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Microwave ablation and synchronous transarterial chemoembolization combined with PD-1 inhibitor in patients with hepatocellular carcinoma following tyrosine kinase inhibitor intolerance.
    Shi Q; Zhou X; Zhang Z; Zhang W; Ma J; Yang M; Yu J; Luo J; Liu L; Yan Z
    Front Immunol; 2022; 13():1097625. PubMed ID: 36703965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy.
    Pinato DJ; Murray SM; Forner A; Kaneko T; Fessas P; Toniutto P; Mínguez B; Cacciato V; Avellini C; Diaz A; Boyton RJ; Altmann DM; Goldin RD; Akarca AU; Marafioti T; Mauri FA; Casagrande E; Grillo F; Giannini E; Bhoori S; Mazzaferro V
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34593621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transarterial Chemoembolization Plus Tyrosinkinase Inhibitors and PD-1 Inhibitors for Spontaneously Ruptured Hepatocellular Carcinoma.
    Ji J; Zhou C; Yan LL; Ma Y; Xu C; Wang FA; Zhou WZ; Lv PH
    Cardiovasc Intervent Radiol; 2024 Mar; 47(3):299-309. PubMed ID: 38291158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.
    Park DJ; Sung PS; Lee GW; Cho S; Kim SM; Kang BY; Hur W; Yang H; Lee SK; Lee SH; Jung ES; Seo CH; Ahn J; Choi HJ; You YK; Jang JW; Bae SH; Choi JY; Yoon SK
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluating the Benefits of TACE Combined with Lenvatinib Plus PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
    Zou X; Xu Q; You R; Yin G
    Adv Ther; 2023 Apr; 40(4):1686-1704. PubMed ID: 36805422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD28/PD1 co-expression: dual impact on CD8
    Palermo B; Franzese O; Frisullo G; D'Ambrosio L; Panetta M; Campo G; D'Andrea D; Sperduti I; De Nicola F; Goeman F; Gallina F; Visca P; Facciolo F; Nisticò P
    J Exp Clin Cancer Res; 2023 Oct; 42(1):287. PubMed ID: 37898752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma.
    Hung YP; Shao YY; Lee JM; Hsu C; Hsu CH; Yang MH; Chao Y
    J Chin Med Assoc; 2021 Feb; 84(2):144-150. PubMed ID: 33433132
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between CD8+ tumor-infiltrating lymphocytes and prognosis of non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitors: a systematic review and meta-analysis.
    Zheng QM; Li YY; Wang YP; Li GX; Zhao MM; Sun ZG
    Expert Rev Anticancer Ther; 2023 Jun; 23(6):643-659. PubMed ID: 37114477
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Short-term curative efficacy of cytokine-induced killer cells combined micro-invasive treatments on hepatocellular carcinoma].
    Zhou QM; Wu PH; Zhao M; Wang QJ; Huang LX; Li YQ; Chen SP; Xia JC
    Ai Zheng; 2006 Nov; 25(11):1414-8. PubMed ID: 17094912
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased circulating Th17 cells after transarterial chemoembolization correlate with improved survival in stage III hepatocellular carcinoma: a prospective study.
    Liao Y; Wang B; Huang ZL; Shi M; Yu XJ; Zheng L; Li S; Li L
    PLoS One; 2013; 8(4):e60444. PubMed ID: 23565248
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.